Jefferies upgrades Chemed to Buy, sees compounder multiple returning on Q3 beat
Jefferies upgraded Chemed (NYSE: CHE) to Buy, raising its price target to $620. The firm cited Q3 earnings beat and operational improvements, particularly in the VITAS hospice division. VITAS saw 12.2% revenue growth and 31.4% EBITDA increase. Roto-Rooter stabilized, and franchise re-acquisitions were noted as growth drivers.
How this was made
The 30-second read
Why it matters
The upgrade and earnings beat provide a fresh catalyst that could attract new buying, especially from institutional investors seeking stable compounders.
Market read
Chemed's stock rallied on the upgrade and earnings beat, indicating short‑term buying opportunity.
What to watch
Potential regulatory changes to Medicare cap rules could affect future margins.
Background
Chemed Corp reported Q3 adjusted EBITDA of $92.5 million, a 31.4% increase, and beat EPS expectations, prompting an analyst upgrade.
Ticker impact
Jefferies upgraded Chemed Corp to Buy and raised its price target to $620 after the Q3 earnings beat, sending shares up 8.7% in Wednesday trade.
upward pressure as the market prices in the upgraded rating and higher target
Analyst upgrade with a substantial price target increase and a strong earnings surprise provide a clear catalyst for near‑term buying.
Market effects
Healthcare services and hospice providers may see broader interest as Chemed's VITAS division demonstrates strong growth.
U.S. mid‑cap healthcare sector could benefit from the positive earnings surprise.
Limited to U.S. investors; no direct global macro impact.
Counterpoint
The upgrade may be premature if VITAS cap limitations re‑emerge or Roto‑Rooter earnings drag returns.
Key entities
- analystJefferies
Upgraded Chemed to Buy and raised price target.
- divisionVITAS Healthcare
Hospice division driving revenue and margin expansion.
